Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Head and Neck Neoplasms | 120 | 2022 | 1035 | 21.410 |
Why?
|
Carcinoma, Squamous Cell | 87 | 2022 | 1046 | 15.200 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 58 | 2022 | 2348 | 7.060 |
Why?
|
Neoplasm Recurrence, Local | 45 | 2022 | 1223 | 6.870 |
Why?
|
Antineoplastic Agents | 49 | 2022 | 2277 | 6.490 |
Why?
|
Quinazolines | 28 | 2019 | 217 | 6.280 |
Why?
|
ErbB Receptors | 29 | 2021 | 475 | 4.850 |
Why?
|
Protein Kinase Inhibitors | 26 | 2021 | 558 | 4.240 |
Why?
|
Antibodies, Monoclonal, Humanized | 23 | 2022 | 897 | 4.080 |
Why?
|
Thyroid Neoplasms | 14 | 2016 | 381 | 3.870 |
Why?
|
Mouth Neoplasms | 16 | 2022 | 189 | 3.530 |
Why?
|
Chemoradiotherapy | 21 | 2022 | 296 | 3.100 |
Why?
|
Cetuximab | 15 | 2022 | 114 | 3.020 |
Why?
|
Indazoles | 8 | 2015 | 69 | 2.270 |
Why?
|
Imidazoles | 8 | 2015 | 161 | 2.150 |
Why?
|
Humans | 208 | 2022 | 80814 | 2.120 |
Why?
|
Disease-Free Survival | 36 | 2021 | 1183 | 2.090 |
Why?
|
Neoplasms | 24 | 2021 | 2684 | 2.060 |
Why?
|
Papillomavirus Infections | 10 | 2022 | 234 | 1.930 |
Why?
|
Biomarkers, Tumor | 16 | 2020 | 1409 | 1.890 |
Why?
|
Oropharyngeal Neoplasms | 6 | 2018 | 122 | 1.850 |
Why?
|
Aged | 93 | 2021 | 17464 | 1.840 |
Why?
|
B7-H1 Antigen | 8 | 2022 | 223 | 1.740 |
Why?
|
Methotrexate | 9 | 2019 | 247 | 1.690 |
Why?
|
Immunotherapy | 9 | 2021 | 569 | 1.680 |
Why?
|
Middle Aged | 92 | 2022 | 23934 | 1.640 |
Why?
|
Sirolimus | 8 | 2018 | 165 | 1.590 |
Why?
|
TOR Serine-Threonine Kinases | 10 | 2021 | 181 | 1.560 |
Why?
|
Female | 113 | 2022 | 42421 | 1.510 |
Why?
|
Male | 104 | 2022 | 39380 | 1.420 |
Why?
|
Aged, 80 and over | 44 | 2021 | 6211 | 1.420 |
Why?
|
Antineoplastic Agents, Immunological | 7 | 2020 | 180 | 1.410 |
Why?
|
Anilides | 6 | 2016 | 45 | 1.410 |
Why?
|
Indoles | 9 | 2016 | 313 | 1.410 |
Why?
|
Programmed Cell Death 1 Receptor | 7 | 2022 | 147 | 1.400 |
Why?
|
Treatment Outcome | 54 | 2021 | 7467 | 1.380 |
Why?
|
Adult | 80 | 2022 | 24602 | 1.370 |
Why?
|
Pyridines | 8 | 2016 | 299 | 1.320 |
Why?
|
Neoplasm Metastasis | 21 | 2021 | 1036 | 1.310 |
Why?
|
Quality of Life | 13 | 2021 | 1392 | 1.250 |
Why?
|
Carcinoma, Papillary | 4 | 2016 | 150 | 1.200 |
Why?
|
Cisplatin | 9 | 2022 | 593 | 1.200 |
Why?
|
Protein-Tyrosine Kinases | 6 | 2012 | 300 | 1.150 |
Why?
|
Everolimus | 4 | 2022 | 39 | 1.140 |
Why?
|
Neoplasm Staging | 26 | 2019 | 1886 | 1.130 |
Why?
|
Molecular Targeted Therapy | 11 | 2021 | 258 | 1.040 |
Why?
|
Drug Resistance, Neoplasm | 7 | 2019 | 561 | 1.000 |
Why?
|
Combined Modality Therapy | 25 | 2020 | 1615 | 0.990 |
Why?
|
Induction Chemotherapy | 11 | 2021 | 143 | 0.970 |
Why?
|
Lung Neoplasms | 10 | 2017 | 2169 | 0.970 |
Why?
|
Papillomaviridae | 7 | 2017 | 151 | 0.940 |
Why?
|
Iodine Radioisotopes | 4 | 2016 | 120 | 0.930 |
Why?
|
Mutation | 19 | 2022 | 3792 | 0.930 |
Why?
|
Salivary Gland Neoplasms | 4 | 2020 | 64 | 0.930 |
Why?
|
Antibodies, Monoclonal | 10 | 2021 | 1352 | 0.900 |
Why?
|
Skin Neoplasms | 3 | 2022 | 512 | 0.890 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 8 | 2017 | 1019 | 0.890 |
Why?
|
Radiopharmaceuticals | 2 | 2015 | 159 | 0.880 |
Why?
|
Proto-Oncogene Proteins c-akt | 7 | 2016 | 309 | 0.870 |
Why?
|
Phenylurea Compounds | 6 | 2015 | 108 | 0.860 |
Why?
|
Survival Analysis | 20 | 2020 | 1513 | 0.840 |
Why?
|
Disease Management | 4 | 2021 | 317 | 0.810 |
Why?
|
Cell Line, Tumor | 16 | 2021 | 2324 | 0.780 |
Why?
|
Nasopharyngeal Neoplasms | 3 | 2015 | 44 | 0.760 |
Why?
|
Laryngeal Neoplasms | 4 | 2013 | 88 | 0.750 |
Why?
|
Prognosis | 21 | 2021 | 3540 | 0.750 |
Why?
|
Patient Selection | 8 | 2021 | 661 | 0.740 |
Why?
|
Cancer Vaccines | 1 | 2020 | 154 | 0.730 |
Why?
|
Signal Transduction | 17 | 2021 | 3147 | 0.710 |
Why?
|
Antigens, Neoplasm | 1 | 2020 | 317 | 0.700 |
Why?
|
Diarrhea | 4 | 2014 | 174 | 0.690 |
Why?
|
Human papillomavirus 16 | 4 | 2019 | 36 | 0.690 |
Why?
|
Kaplan-Meier Estimate | 9 | 2018 | 839 | 0.690 |
Why?
|
Vascular Endothelial Growth Factor A | 5 | 2014 | 373 | 0.680 |
Why?
|
Benzazepines | 1 | 2018 | 87 | 0.680 |
Why?
|
Proto-Oncogene Proteins c-kit | 2 | 2015 | 79 | 0.670 |
Why?
|
Survivors | 2 | 2016 | 209 | 0.650 |
Why?
|
Quinolines | 2 | 2015 | 89 | 0.650 |
Why?
|
Angiogenesis Inhibitors | 7 | 2015 | 296 | 0.640 |
Why?
|
Clinical Trials as Topic | 10 | 2016 | 1141 | 0.640 |
Why?
|
Clinical Protocols | 2 | 2014 | 153 | 0.630 |
Why?
|
Fluorouracil | 15 | 2014 | 548 | 0.630 |
Why?
|
Research Design | 5 | 2014 | 566 | 0.620 |
Why?
|
Survival Rate | 12 | 2016 | 1813 | 0.620 |
Why?
|
Precision Medicine | 4 | 2021 | 363 | 0.620 |
Why?
|
Killer Cells, Natural | 2 | 2017 | 307 | 0.610 |
Why?
|
Receptor, ErbB-2 | 5 | 2017 | 198 | 0.610 |
Why?
|
Hypopharyngeal Neoplasms | 2 | 2013 | 15 | 0.600 |
Why?
|
Carcinoma, Adenoid Cystic | 2 | 2015 | 27 | 0.600 |
Why?
|
Dasatinib | 1 | 2015 | 35 | 0.580 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 5 | 2021 | 50 | 0.580 |
Why?
|
Administration, Oral | 9 | 2017 | 678 | 0.570 |
Why?
|
Erlotinib Hydrochloride | 6 | 2016 | 90 | 0.560 |
Why?
|
Tumor Microenvironment | 6 | 2022 | 336 | 0.560 |
Why?
|
Mice, Nude | 8 | 2016 | 752 | 0.560 |
Why?
|
Aftercare | 1 | 2016 | 62 | 0.560 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 1 | 2015 | 22 | 0.560 |
Why?
|
Precancerous Conditions | 4 | 2016 | 191 | 0.550 |
Why?
|
Drug Administration Schedule | 8 | 2018 | 915 | 0.550 |
Why?
|
Glutamates | 2 | 2012 | 89 | 0.540 |
Why?
|
Anticarcinogenic Agents | 2 | 2016 | 70 | 0.540 |
Why?
|
Antibiotics, Antineoplastic | 2 | 2012 | 108 | 0.540 |
Why?
|
Practice Guidelines as Topic | 4 | 2019 | 1013 | 0.540 |
Why?
|
Double-Blind Method | 7 | 2021 | 1774 | 0.530 |
Why?
|
Maximum Tolerated Dose | 10 | 2017 | 268 | 0.530 |
Why?
|
Adaptor Proteins, Signal Transducing | 4 | 2016 | 289 | 0.530 |
Why?
|
Guanine | 2 | 2012 | 206 | 0.510 |
Why?
|
Palliative Care | 2 | 2015 | 234 | 0.510 |
Why?
|
Radiodermatitis | 1 | 2013 | 11 | 0.500 |
Why?
|
Mucositis | 1 | 2013 | 16 | 0.500 |
Why?
|
Neovascularization, Pathologic | 3 | 2015 | 336 | 0.500 |
Why?
|
Neoplasm Invasiveness | 4 | 2012 | 516 | 0.500 |
Why?
|
Pyrroles | 4 | 2015 | 182 | 0.490 |
Why?
|
Food-Drug Interactions | 1 | 2013 | 18 | 0.480 |
Why?
|
Hot Temperature | 1 | 2013 | 198 | 0.470 |
Why?
|
Antimetabolites, Antineoplastic | 4 | 2017 | 235 | 0.460 |
Why?
|
Information Dissemination | 1 | 2013 | 100 | 0.460 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 5 | 2014 | 58 | 0.460 |
Why?
|
Publishing | 1 | 2013 | 86 | 0.460 |
Why?
|
Disease Progression | 10 | 2020 | 1432 | 0.460 |
Why?
|
Surveys and Questionnaires | 6 | 2018 | 2284 | 0.450 |
Why?
|
Hydroxyurea | 12 | 2014 | 239 | 0.450 |
Why?
|
Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2011 | 20 | 0.440 |
Why?
|
Health Status | 1 | 2014 | 344 | 0.440 |
Why?
|
Clinical Trials, Phase III as Topic | 6 | 2022 | 159 | 0.440 |
Why?
|
Radiation Tolerance | 4 | 2016 | 167 | 0.440 |
Why?
|
Carcinoma, Large Cell | 1 | 2011 | 39 | 0.430 |
Why?
|
Adenocarcinoma, Follicular | 1 | 2012 | 51 | 0.430 |
Why?
|
Sulfonamides | 5 | 2016 | 288 | 0.420 |
Why?
|
Periodicals as Topic | 1 | 2013 | 161 | 0.420 |
Why?
|
Immunologic Factors | 3 | 2021 | 163 | 0.420 |
Why?
|
Radiation-Sensitizing Agents | 2 | 2012 | 95 | 0.420 |
Why?
|
Mitogen-Activated Protein Kinases | 3 | 2008 | 220 | 0.410 |
Why?
|
Bevacizumab | 6 | 2011 | 269 | 0.410 |
Why?
|
Benzimidazoles | 1 | 2012 | 135 | 0.410 |
Why?
|
Retreatment | 5 | 2015 | 106 | 0.410 |
Why?
|
Thyroid Gland | 1 | 2012 | 261 | 0.400 |
Why?
|
Patient Care Team | 1 | 2013 | 268 | 0.400 |
Why?
|
Radiotherapy Dosage | 10 | 2016 | 485 | 0.390 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 4 | 2015 | 77 | 0.390 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2022 | 103 | 0.390 |
Why?
|
Receptor Protein-Tyrosine Kinases | 2 | 2011 | 152 | 0.380 |
Why?
|
Mice | 13 | 2021 | 10810 | 0.380 |
Why?
|
Proto-Oncogene Proteins c-ret | 3 | 2016 | 18 | 0.380 |
Why?
|
Clinical Trials, Phase II as Topic | 4 | 2022 | 170 | 0.370 |
Why?
|
Dose-Response Relationship, Drug | 10 | 2017 | 1939 | 0.370 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2010 | 124 | 0.370 |
Why?
|
Randomized Controlled Trials as Topic | 6 | 2022 | 804 | 0.370 |
Why?
|
Animals | 19 | 2021 | 25628 | 0.360 |
Why?
|
Protein Kinase C-alpha | 1 | 2009 | 27 | 0.360 |
Why?
|
Immunohistochemistry | 7 | 2020 | 1714 | 0.360 |
Why?
|
Young Adult | 11 | 2019 | 5713 | 0.350 |
Why?
|
Phosphatidylinositol 3-Kinases | 3 | 2015 | 248 | 0.350 |
Why?
|
Positron-Emission Tomography | 1 | 2010 | 277 | 0.350 |
Why?
|
Skin | 1 | 2012 | 542 | 0.350 |
Why?
|
Proto-Oncogene Proteins B-raf | 3 | 2016 | 131 | 0.350 |
Why?
|
Thalidomide | 3 | 2015 | 51 | 0.350 |
Why?
|
United States | 14 | 2020 | 6167 | 0.340 |
Why?
|
ras Proteins | 3 | 2016 | 127 | 0.330 |
Why?
|
Adenocarcinoma | 3 | 2011 | 1125 | 0.330 |
Why?
|
Esophageal Neoplasms | 3 | 2017 | 304 | 0.330 |
Why?
|
Lymphocyte Activation | 3 | 2020 | 736 | 0.330 |
Why?
|
Pharmacogenetics | 1 | 2012 | 424 | 0.330 |
Why?
|
Platinum | 5 | 2016 | 61 | 0.330 |
Why?
|
Radiotherapy | 6 | 2020 | 325 | 0.320 |
Why?
|
Medical Oncology | 3 | 2018 | 332 | 0.320 |
Why?
|
Retrospective Studies | 16 | 2020 | 7532 | 0.320 |
Why?
|
Chemotherapy, Adjuvant | 7 | 2021 | 447 | 0.320 |
Why?
|
DNA-Binding Proteins | 4 | 2016 | 1189 | 0.310 |
Why?
|
Triazines | 1 | 2007 | 45 | 0.310 |
Why?
|
Biopsy | 3 | 2020 | 1124 | 0.310 |
Why?
|
Protein Kinases | 1 | 2008 | 204 | 0.310 |
Why?
|
Niacinamide | 5 | 2014 | 116 | 0.300 |
Why?
|
DNA, Neoplasm | 3 | 2017 | 266 | 0.300 |
Why?
|
Prospective Studies | 6 | 2022 | 3915 | 0.300 |
Why?
|
Eating | 1 | 2007 | 167 | 0.300 |
Why?
|
Genomics | 4 | 2015 | 649 | 0.300 |
Why?
|
Xenograft Model Antitumor Assays | 6 | 2021 | 439 | 0.300 |
Why?
|
Time Factors | 9 | 2020 | 5087 | 0.300 |
Why?
|
Epidermal Growth Factor | 1 | 2006 | 120 | 0.290 |
Why?
|
Immunotoxins | 1 | 2005 | 13 | 0.290 |
Why?
|
Ribosomal Protein S6 Kinases, 70-kDa | 3 | 2018 | 44 | 0.290 |
Why?
|
Oligonucleotides, Antisense | 1 | 2005 | 68 | 0.290 |
Why?
|
B-Lymphocytes | 2 | 2021 | 723 | 0.280 |
Why?
|
Deoxycytidine | 2 | 2011 | 235 | 0.280 |
Why?
|
Tongue Neoplasms | 3 | 2017 | 52 | 0.280 |
Why?
|
Drug Approval | 2 | 2019 | 59 | 0.280 |
Why?
|
Tumor Escape | 3 | 2020 | 48 | 0.280 |
Why?
|
Viral Vaccines | 2 | 2003 | 42 | 0.280 |
Why?
|
United States Food and Drug Administration | 2 | 2019 | 119 | 0.280 |
Why?
|
Protein Kinase C | 1 | 2006 | 270 | 0.280 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 2 | 2020 | 142 | 0.280 |
Why?
|
Fatigue | 3 | 2016 | 166 | 0.270 |
Why?
|
Risk Factors | 11 | 2019 | 5122 | 0.270 |
Why?
|
Vinblastine | 2 | 2002 | 108 | 0.270 |
Why?
|
Genes, p53 | 2 | 2015 | 109 | 0.260 |
Why?
|
T-Lymphocytes | 3 | 2020 | 1189 | 0.260 |
Why?
|
Evidence-Based Dentistry | 3 | 2017 | 10 | 0.260 |
Why?
|
Chromosome Deletion | 2 | 2015 | 226 | 0.250 |
Why?
|
Receptor, ErbB-3 | 2 | 2021 | 18 | 0.250 |
Why?
|
MicroRNAs | 1 | 2009 | 510 | 0.250 |
Why?
|
Piperazines | 3 | 2017 | 261 | 0.250 |
Why?
|
Cell Proliferation | 5 | 2021 | 1539 | 0.250 |
Why?
|
Mitochondria | 1 | 2007 | 517 | 0.250 |
Why?
|
Deglutition | 3 | 2013 | 67 | 0.240 |
Why?
|
Drug Screening Assays, Antitumor | 2 | 2015 | 77 | 0.240 |
Why?
|
Biomarkers | 6 | 2021 | 1600 | 0.240 |
Why?
|
MAP Kinase Signaling System | 2 | 2016 | 188 | 0.240 |
Why?
|
Smoking | 5 | 2014 | 593 | 0.240 |
Why?
|
Alcohol Drinking | 4 | 2013 | 258 | 0.230 |
Why?
|
Immunomodulation | 2 | 2021 | 55 | 0.230 |
Why?
|
Pain Management | 2 | 2015 | 119 | 0.230 |
Why?
|
Carboplatin | 6 | 2019 | 281 | 0.230 |
Why?
|
Follow-Up Studies | 10 | 2018 | 3528 | 0.230 |
Why?
|
Neoplasms, Second Primary | 3 | 2011 | 247 | 0.220 |
Why?
|
Cell Cycle | 3 | 2010 | 496 | 0.220 |
Why?
|
Cohort Studies | 7 | 2019 | 2579 | 0.220 |
Why?
|
Drug Monitoring | 2 | 2019 | 115 | 0.220 |
Why?
|
Deglutition Disorders | 2 | 2016 | 99 | 0.220 |
Why?
|
Pemetrexed | 2 | 2012 | 76 | 0.210 |
Why?
|
Mechanistic Target of Rapamycin Complex 1 | 1 | 2021 | 27 | 0.210 |
Why?
|
Genetic Therapy | 2 | 2012 | 334 | 0.210 |
Why?
|
Adenoviridae | 2 | 2003 | 344 | 0.210 |
Why?
|
Clinical Competence | 2 | 2018 | 720 | 0.210 |
Why?
|
Germany | 1 | 2021 | 72 | 0.210 |
Why?
|
Benzenesulfonates | 3 | 2011 | 63 | 0.210 |
Why?
|
Muscle Neoplasms | 1 | 2001 | 18 | 0.210 |
Why?
|
Gene Deletion | 2 | 2014 | 327 | 0.210 |
Why?
|
Germ-Line Mutation | 2 | 2022 | 307 | 0.210 |
Why?
|
Immunogenicity, Vaccine | 1 | 2020 | 12 | 0.210 |
Why?
|
Taxoids | 2 | 2014 | 128 | 0.210 |
Why?
|
Immune System | 1 | 2021 | 88 | 0.210 |
Why?
|
Salvage Therapy | 2 | 2016 | 228 | 0.200 |
Why?
|
Placebos | 1 | 2021 | 217 | 0.200 |
Why?
|
Standard of Care | 1 | 2021 | 86 | 0.200 |
Why?
|
Carcinoma | 3 | 2015 | 422 | 0.200 |
Why?
|
Vaccines, Subunit | 1 | 2020 | 55 | 0.200 |
Why?
|
Oncolytic Virotherapy | 1 | 2020 | 40 | 0.200 |
Why?
|
Doxorubicin | 1 | 2001 | 280 | 0.200 |
Why?
|
Heterografts | 2 | 2017 | 90 | 0.200 |
Why?
|
Radiotherapy, Intensity-Modulated | 3 | 2019 | 181 | 0.200 |
Why?
|
Rimantadine | 1 | 2019 | 9 | 0.200 |
Why?
|
Paclitaxel | 6 | 2012 | 451 | 0.190 |
Why?
|
Quinolones | 1 | 2020 | 56 | 0.190 |
Why?
|
Oncogene Proteins, Viral | 1 | 2019 | 33 | 0.190 |
Why?
|
Patient Reported Outcome Measures | 1 | 2021 | 138 | 0.190 |
Why?
|
Clinical Trials, Phase I as Topic | 3 | 2014 | 147 | 0.190 |
Why?
|
Nomograms | 1 | 2019 | 26 | 0.190 |
Why?
|
Age Factors | 3 | 2019 | 1775 | 0.190 |
Why?
|
DNA Mutational Analysis | 2 | 2015 | 519 | 0.180 |
Why?
|
Decision Support Techniques | 1 | 2020 | 152 | 0.180 |
Why?
|
Models, Immunological | 1 | 2019 | 85 | 0.180 |
Why?
|
CTLA-4 Antigen | 1 | 2019 | 133 | 0.180 |
Why?
|
Blood Pressure | 3 | 2014 | 1107 | 0.180 |
Why?
|
Drug Synergism | 3 | 2018 | 299 | 0.180 |
Why?
|
Epithelial Cells | 1 | 2022 | 617 | 0.180 |
Why?
|
Carcinoma, Neuroendocrine | 3 | 2013 | 27 | 0.170 |
Why?
|
Palliative Medicine | 1 | 2018 | 11 | 0.170 |
Why?
|
Biological Products | 1 | 2020 | 129 | 0.170 |
Why?
|
Genotype | 2 | 2015 | 1812 | 0.170 |
Why?
|
Chromosomes, Human, Pair 3 | 2 | 2015 | 54 | 0.170 |
Why?
|
Toll-Like Receptor 7 | 1 | 2017 | 6 | 0.170 |
Why?
|
Toll-Like Receptor 9 | 1 | 2017 | 20 | 0.170 |
Why?
|
Risk Assessment | 6 | 2016 | 2168 | 0.170 |
Why?
|
Administration, Intravenous | 1 | 2017 | 45 | 0.170 |
Why?
|
Cell Growth Processes | 2 | 2009 | 79 | 0.170 |
Why?
|
Consensus | 1 | 2019 | 296 | 0.160 |
Why?
|
Immune Tolerance | 2 | 2019 | 326 | 0.160 |
Why?
|
Vascular Endothelial Growth Factor Receptor-3 | 2 | 2015 | 24 | 0.160 |
Why?
|
Immunoglobulin G | 1 | 2019 | 443 | 0.160 |
Why?
|
Transforming Growth Factor alpha | 2 | 2009 | 48 | 0.160 |
Why?
|
Evidence-Based Medicine | 2 | 2015 | 417 | 0.160 |
Why?
|
Mouth Mucosa | 2 | 2009 | 66 | 0.160 |
Why?
|
Confidence Intervals | 4 | 2019 | 222 | 0.160 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2001 | 349 | 0.160 |
Why?
|
Macrophages | 2 | 2017 | 530 | 0.160 |
Why?
|
SOX9 Transcription Factor | 1 | 2016 | 22 | 0.160 |
Why?
|
Population Surveillance | 2 | 2018 | 218 | 0.160 |
Why?
|
Circulating Tumor DNA | 1 | 2017 | 23 | 0.160 |
Why?
|
Pyrazines | 2 | 2022 | 84 | 0.160 |
Why?
|
Class Ib Phosphatidylinositol 3-Kinase | 1 | 2016 | 4 | 0.160 |
Why?
|
Mice, Inbred C3H | 1 | 2017 | 373 | 0.160 |
Why?
|
Gene Expression | 2 | 2014 | 1272 | 0.160 |
Why?
|
Proto-Oncogenes | 1 | 2016 | 61 | 0.160 |
Why?
|
DNA Copy Number Variations | 2 | 2015 | 169 | 0.160 |
Why?
|
Gene Amplification | 2 | 2015 | 130 | 0.160 |
Why?
|
Metformin | 1 | 2018 | 114 | 0.150 |
Why?
|
Models, Biological | 3 | 2014 | 1720 | 0.150 |
Why?
|
Predictive Value of Tests | 2 | 2020 | 1604 | 0.150 |
Why?
|
Base Sequence | 3 | 2014 | 2313 | 0.150 |
Why?
|
Tomography, X-Ray Computed | 3 | 2019 | 2441 | 0.150 |
Why?
|
Accessory Nerve Diseases | 1 | 2016 | 1 | 0.150 |
Why?
|
Dental Caries | 1 | 2016 | 4 | 0.150 |
Why?
|
Taste Disorders | 1 | 2016 | 7 | 0.150 |
Why?
|
Trismus | 1 | 2016 | 6 | 0.150 |
Why?
|
Vestibular Neuronitis | 1 | 2016 | 2 | 0.150 |
Why?
|
Mass Screening | 2 | 2012 | 596 | 0.150 |
Why?
|
Xerostomia | 1 | 2016 | 9 | 0.150 |
Why?
|
Respiratory Aspiration | 1 | 2016 | 5 | 0.150 |
Why?
|
Periodontitis | 1 | 2016 | 6 | 0.150 |
Why?
|
Benzamides | 2 | 2022 | 220 | 0.150 |
Why?
|
Voice Disorders | 1 | 2016 | 6 | 0.150 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 2 | 2015 | 89 | 0.150 |
Why?
|
American Cancer Society | 1 | 2016 | 14 | 0.150 |
Why?
|
Dental Care | 1 | 2016 | 11 | 0.150 |
Why?
|
Stomatitis | 1 | 2016 | 30 | 0.150 |
Why?
|
Neck Muscles | 1 | 2016 | 15 | 0.150 |
Why?
|
Osteonecrosis | 1 | 2016 | 21 | 0.150 |
Why?
|
Bursitis | 1 | 2016 | 11 | 0.150 |
Why?
|
In Situ Hybridization, Fluorescence | 3 | 2012 | 348 | 0.150 |
Why?
|
Dystonia | 1 | 2016 | 28 | 0.150 |
Why?
|
Pyrimidinones | 1 | 2016 | 29 | 0.150 |
Why?
|
Peptide Hormones | 1 | 2016 | 29 | 0.150 |
Why?
|
Pyridones | 1 | 2016 | 48 | 0.150 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2015 | 102 | 0.140 |
Why?
|
Proto-Oncogene Proteins | 2 | 2010 | 646 | 0.140 |
Why?
|
Societies, Medical | 1 | 2019 | 564 | 0.140 |
Why?
|
Collagen Type I | 1 | 2015 | 62 | 0.140 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2016 | 82 | 0.140 |
Why?
|
Matrix Metalloproteinases | 1 | 2015 | 27 | 0.140 |
Why?
|
Sleep Apnea Syndromes | 1 | 2016 | 97 | 0.140 |
Why?
|
Pneumonia, Aspiration | 1 | 2014 | 18 | 0.140 |
Why?
|
Receptors, IgG | 1 | 2015 | 51 | 0.140 |
Why?
|
Apoptosis | 4 | 2017 | 1645 | 0.130 |
Why?
|
Sleep Wake Disorders | 1 | 2016 | 107 | 0.130 |
Why?
|
Proteomics | 2 | 2022 | 192 | 0.130 |
Why?
|
Multivariate Analysis | 3 | 2019 | 959 | 0.130 |
Why?
|
Lymphedema | 1 | 2016 | 74 | 0.130 |
Why?
|
Stomach Neoplasms | 1 | 2017 | 251 | 0.130 |
Why?
|
Cost-Benefit Analysis | 2 | 2020 | 422 | 0.130 |
Why?
|
Ubiquitin-Activating Enzymes | 1 | 2014 | 6 | 0.130 |
Why?
|
Gastroesophageal Reflux | 1 | 2016 | 111 | 0.130 |
Why?
|
Autophagy-Related Protein 7 | 1 | 2014 | 12 | 0.130 |
Why?
|
Hypothyroidism | 1 | 2016 | 216 | 0.130 |
Why?
|
Health Promotion | 1 | 2016 | 154 | 0.130 |
Why?
|
Phosphorylation | 2 | 2018 | 1095 | 0.130 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2014 | 24 | 0.130 |
Why?
|
Neoplasm Grading | 1 | 2015 | 323 | 0.130 |
Why?
|
Sequestosome-1 Protein | 1 | 2014 | 22 | 0.130 |
Why?
|
Tumor Virus Infections | 1 | 2014 | 79 | 0.130 |
Why?
|
Education, Medical, Graduate | 1 | 2018 | 344 | 0.130 |
Why?
|
Drug Interactions | 3 | 2011 | 246 | 0.130 |
Why?
|
Anxiety | 1 | 2016 | 249 | 0.130 |
Why?
|
Focus Groups | 1 | 2014 | 139 | 0.130 |
Why?
|
Transcription Factors | 2 | 2016 | 1484 | 0.130 |
Why?
|
Peptide Fragments | 1 | 2016 | 451 | 0.130 |
Why?
|
Licensure | 1 | 2013 | 5 | 0.130 |
Why?
|
Quinoxalines | 1 | 2014 | 49 | 0.130 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2017 | 525 | 0.130 |
Why?
|
Pediatrics | 1 | 2018 | 336 | 0.130 |
Why?
|
Tissue Array Analysis | 1 | 2014 | 121 | 0.130 |
Why?
|
Population Groups | 1 | 2013 | 41 | 0.120 |
Why?
|
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2013 | 72 | 0.120 |
Why?
|
DNA Primers | 2 | 2014 | 536 | 0.120 |
Why?
|
Peer Review | 1 | 2013 | 23 | 0.120 |
Why?
|
Leukoplakia, Oral | 1 | 2013 | 10 | 0.120 |
Why?
|
Neoadjuvant Therapy | 3 | 2018 | 274 | 0.120 |
Why?
|
Aminolevulinic Acid | 1 | 2013 | 21 | 0.120 |
Why?
|
Breast Neoplasms | 2 | 2017 | 2764 | 0.120 |
Why?
|
Receptor, ErbB-4 | 1 | 2013 | 5 | 0.120 |
Why?
|
Erythropoiesis | 1 | 2013 | 50 | 0.120 |
Why?
|
Economics, Pharmaceutical | 1 | 2013 | 8 | 0.120 |
Why?
|
Regression Analysis | 2 | 2019 | 586 | 0.120 |
Why?
|
Photosensitizing Agents | 1 | 2013 | 46 | 0.120 |
Why?
|
Statistics, Nonparametric | 3 | 2009 | 299 | 0.120 |
Why?
|
Qualitative Research | 1 | 2014 | 238 | 0.120 |
Why?
|
Interviews as Topic | 1 | 2014 | 314 | 0.120 |
Why?
|
Area Under Curve | 5 | 2014 | 325 | 0.120 |
Why?
|
Italy | 1 | 2013 | 102 | 0.120 |
Why?
|
Magnetics | 1 | 2013 | 44 | 0.120 |
Why?
|
Colorectal Neoplasms | 2 | 2011 | 874 | 0.120 |
Why?
|
Genetic Association Studies | 1 | 2015 | 290 | 0.120 |
Why?
|
Micelles | 1 | 2013 | 45 | 0.120 |
Why?
|
United Kingdom | 1 | 2013 | 158 | 0.120 |
Why?
|
Gastrostomy | 1 | 2013 | 65 | 0.120 |
Why?
|
Stress, Psychological | 1 | 2016 | 292 | 0.120 |
Why?
|
Citrus paradisi | 1 | 2012 | 5 | 0.120 |
Why?
|
Photochemotherapy | 1 | 2013 | 94 | 0.120 |
Why?
|
Antineoplastic Agents, Phytogenic | 2 | 2012 | 276 | 0.120 |
Why?
|
Ketoconazole | 1 | 2012 | 25 | 0.120 |
Why?
|
Gene Expression Profiling | 3 | 2014 | 1328 | 0.120 |
Why?
|
Lymphopenia | 1 | 2012 | 30 | 0.120 |
Why?
|
Dose-Response Relationship, Radiation | 2 | 2009 | 189 | 0.110 |
Why?
|
Depression | 1 | 2016 | 421 | 0.110 |
Why?
|
Sexual Partners | 1 | 2013 | 89 | 0.110 |
Why?
|
Platinum Compounds | 1 | 2012 | 29 | 0.110 |
Why?
|
Autophagy | 1 | 2014 | 142 | 0.110 |
Why?
|
DNA Repair | 1 | 2014 | 347 | 0.110 |
Why?
|
Biopsy, Needle | 1 | 2012 | 232 | 0.110 |
Why?
|
Pyrimidines | 2 | 2014 | 359 | 0.110 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2014 | 377 | 0.110 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2014 | 365 | 0.110 |
Why?
|
Hyperlipidemias | 1 | 2012 | 94 | 0.110 |
Why?
|
Exanthema | 1 | 2012 | 30 | 0.110 |
Why?
|
RNA, Viral | 1 | 2013 | 319 | 0.110 |
Why?
|
Radiography | 2 | 2014 | 790 | 0.110 |
Why?
|
Peptides | 1 | 2015 | 615 | 0.110 |
Why?
|
Bibenzyls | 1 | 2011 | 2 | 0.110 |
Why?
|
Feasibility Studies | 2 | 2019 | 725 | 0.110 |
Why?
|
RNA, Small Interfering | 2 | 2010 | 538 | 0.110 |
Why?
|
Lactams, Macrocyclic | 1 | 2011 | 14 | 0.110 |
Why?
|
Valproic Acid | 1 | 2011 | 21 | 0.110 |
Why?
|
Benzoquinones | 1 | 2011 | 27 | 0.110 |
Why?
|
Radiotherapy, Adjuvant | 3 | 2008 | 287 | 0.110 |
Why?
|
Depsipeptides | 1 | 2011 | 29 | 0.110 |
Why?
|
Hyperglycemia | 1 | 2012 | 170 | 0.110 |
Why?
|
Nanoparticles | 1 | 2013 | 155 | 0.100 |
Why?
|
Hydroxamic Acids | 1 | 2011 | 47 | 0.100 |
Why?
|
Tracheotomy | 1 | 2011 | 18 | 0.100 |
Why?
|
Boronic Acids | 1 | 2011 | 54 | 0.100 |
Why?
|
Bortezomib | 1 | 2011 | 72 | 0.100 |
Why?
|
In Situ Nick-End Labeling | 1 | 2011 | 119 | 0.100 |
Why?
|
Imatinib Mesylate | 1 | 2011 | 122 | 0.100 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2011 | 45 | 0.100 |
Why?
|
Psoriasis | 1 | 2014 | 229 | 0.100 |
Why?
|
Carbazoles | 1 | 2011 | 51 | 0.100 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2011 | 81 | 0.100 |
Why?
|
Chemoprevention | 1 | 2011 | 88 | 0.100 |
Why?
|
Oligonucleotides | 1 | 2011 | 90 | 0.100 |
Why?
|
Cyclin D1 | 1 | 2010 | 80 | 0.100 |
Why?
|
Camptothecin | 1 | 2011 | 189 | 0.100 |
Why?
|
Neoplasm Transplantation | 1 | 2011 | 381 | 0.100 |
Why?
|
Sexual Behavior | 1 | 2013 | 272 | 0.100 |
Why?
|
Speech | 1 | 2010 | 74 | 0.100 |
Why?
|
Probability | 5 | 2009 | 344 | 0.100 |
Why?
|
Airway Obstruction | 1 | 2011 | 108 | 0.100 |
Why?
|
Piperidines | 1 | 2011 | 175 | 0.090 |
Why?
|
Antigen-Presenting Cells | 2 | 2021 | 144 | 0.090 |
Why?
|
Cell Cycle Proteins | 2 | 2010 | 376 | 0.090 |
Why?
|
Thermography | 1 | 2009 | 11 | 0.090 |
Why?
|
Mass Spectrometry | 1 | 2010 | 183 | 0.090 |
Why?
|
Transplantation, Heterologous | 1 | 2010 | 346 | 0.090 |
Why?
|
Biomedical Research | 1 | 2013 | 348 | 0.090 |
Why?
|
Referral and Consultation | 1 | 2012 | 303 | 0.090 |
Why?
|
Receptors, Growth Factor | 1 | 2009 | 52 | 0.090 |
Why?
|
Tumor Cells, Cultured | 1 | 2011 | 1031 | 0.090 |
Why?
|
Endpoint Determination | 1 | 2009 | 59 | 0.090 |
Why?
|
Cyclin E | 1 | 2009 | 27 | 0.090 |
Why?
|
Internship and Residency | 1 | 2018 | 929 | 0.090 |
Why?
|
Demography | 1 | 2009 | 159 | 0.090 |
Why?
|
Cell Line | 2 | 2011 | 2429 | 0.090 |
Why?
|
Radiotherapy, High-Energy | 1 | 2008 | 49 | 0.090 |
Why?
|
Cell Survival | 1 | 2011 | 959 | 0.090 |
Why?
|
Adolescent | 6 | 2019 | 8656 | 0.090 |
Why?
|
Radiosurgery | 1 | 2011 | 263 | 0.090 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2010 | 680 | 0.080 |
Why?
|
Amino Acid Sequence | 2 | 2016 | 2059 | 0.080 |
Why?
|
Economics, Medical | 1 | 2007 | 6 | 0.080 |
Why?
|
Research | 1 | 2009 | 248 | 0.080 |
Why?
|
Drug Packaging | 1 | 2007 | 7 | 0.080 |
Why?
|
Analysis of Variance | 2 | 2008 | 895 | 0.080 |
Why?
|
Drug Labeling | 1 | 2007 | 40 | 0.080 |
Why?
|
Carcinoma, Renal Cell | 1 | 2011 | 402 | 0.080 |
Why?
|
Molecular Sequence Data | 2 | 2016 | 3026 | 0.080 |
Why?
|
Polymorphism, Genetic | 1 | 2011 | 812 | 0.080 |
Why?
|
Benzophenanthridines | 1 | 2006 | 23 | 0.080 |
Why?
|
DNA, Mitochondrial | 1 | 2007 | 180 | 0.080 |
Why?
|
Butadienes | 1 | 2006 | 33 | 0.080 |
Why?
|
Remission Induction | 3 | 2016 | 692 | 0.080 |
Why?
|
Phenanthridines | 1 | 2006 | 24 | 0.080 |
Why?
|
DNA | 1 | 2012 | 1250 | 0.080 |
Why?
|
Alkaloids | 1 | 2006 | 45 | 0.080 |
Why?
|
Phosphorylcholine | 1 | 2006 | 28 | 0.080 |
Why?
|
Phenotype | 1 | 2012 | 2283 | 0.070 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2015 | 2303 | 0.070 |
Why?
|
Nitriles | 1 | 2006 | 140 | 0.070 |
Why?
|
Surgical Flaps | 1 | 2008 | 245 | 0.070 |
Why?
|
Early Detection of Cancer | 3 | 2017 | 350 | 0.070 |
Why?
|
Kidney Neoplasms | 1 | 2011 | 588 | 0.070 |
Why?
|
American Dental Association | 2 | 2017 | 10 | 0.070 |
Why?
|
Keratinocytes | 1 | 2006 | 135 | 0.070 |
Why?
|
Preoperative Care | 2 | 2006 | 382 | 0.070 |
Why?
|
Cyclooxygenase Inhibitors | 1 | 2004 | 40 | 0.070 |
Why?
|
SEER Program | 2 | 2016 | 180 | 0.070 |
Why?
|
Proteasome Inhibitors | 1 | 2004 | 49 | 0.070 |
Why?
|
Enzyme Activation | 1 | 2006 | 689 | 0.070 |
Why?
|
Hypoxia-Inducible Factor 1 | 1 | 2004 | 42 | 0.070 |
Why?
|
Incidence | 3 | 2017 | 1534 | 0.060 |
Why?
|
Mouthwashes | 1 | 2003 | 5 | 0.060 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2006 | 406 | 0.060 |
Why?
|
Colonic Neoplasms | 1 | 2008 | 538 | 0.060 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2004 | 147 | 0.060 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 1 | 2003 | 68 | 0.060 |
Why?
|
CCAAT-Enhancer-Binding Protein-beta | 2 | 2016 | 12 | 0.060 |
Why?
|
Intubation, Gastrointestinal | 1 | 2003 | 28 | 0.060 |
Why?
|
Disease Models, Animal | 2 | 2020 | 2157 | 0.060 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2019 | 1163 | 0.060 |
Why?
|
Odds Ratio | 2 | 2018 | 648 | 0.060 |
Why?
|
Medicare | 2 | 2016 | 332 | 0.060 |
Why?
|
Infusions, Intravenous | 3 | 2009 | 429 | 0.060 |
Why?
|
Inflammation | 2 | 2019 | 839 | 0.060 |
Why?
|
Isotretinoin | 1 | 2002 | 23 | 0.060 |
Why?
|
Illinois | 1 | 2003 | 450 | 0.050 |
Why?
|
Sex Factors | 2 | 2014 | 1020 | 0.050 |
Why?
|
Cytodiagnosis | 2 | 2012 | 41 | 0.050 |
Why?
|
Interferon-alpha | 1 | 2002 | 232 | 0.050 |
Why?
|
Antibody Formation | 1 | 2021 | 168 | 0.050 |
Why?
|
Lymphopoiesis | 1 | 2021 | 49 | 0.050 |
Why?
|
Urothelium | 1 | 2001 | 62 | 0.050 |
Why?
|
Structure-Activity Relationship | 1 | 2001 | 400 | 0.050 |
Why?
|
RAW 264.7 Cells | 1 | 2019 | 15 | 0.050 |
Why?
|
Nuclear Proteins | 1 | 2004 | 682 | 0.050 |
Why?
|
Child | 3 | 2018 | 6538 | 0.050 |
Why?
|
Treatment Adherence and Compliance | 1 | 2019 | 5 | 0.050 |
Why?
|
Models, Economic | 1 | 2020 | 60 | 0.050 |
Why?
|
Thinness | 1 | 2019 | 42 | 0.050 |
Why?
|
Employment | 1 | 2019 | 49 | 0.050 |
Why?
|
Smokers | 1 | 2019 | 36 | 0.050 |
Why?
|
Receptors, Cytokine | 1 | 2019 | 27 | 0.050 |
Why?
|
Veterans | 1 | 2019 | 59 | 0.050 |
Why?
|
Quality-Adjusted Life Years | 1 | 2020 | 130 | 0.050 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2019 | 161 | 0.050 |
Why?
|
Healthy Volunteers | 1 | 2019 | 133 | 0.050 |
Why?
|
Hospitals, Veterans | 1 | 2018 | 16 | 0.050 |
Why?
|
Equivalence Trials as Topic | 1 | 2018 | 5 | 0.040 |
Why?
|
Training Support | 1 | 2018 | 23 | 0.040 |
Why?
|
Insulin-Like Growth Factor II | 1 | 2018 | 33 | 0.040 |
Why?
|
Interdisciplinary Studies | 1 | 2018 | 20 | 0.040 |
Why?
|
Clinical Decision-Making | 1 | 2020 | 243 | 0.040 |
Why?
|
Organ Specificity | 1 | 2019 | 253 | 0.040 |
Why?
|
Laryngectomy | 1 | 2018 | 26 | 0.040 |
Why?
|
Antigen Presentation | 1 | 2019 | 226 | 0.040 |
Why?
|
Down-Regulation | 1 | 2019 | 496 | 0.040 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 192 | 0.040 |
Why?
|
Autoimmunity | 1 | 2019 | 157 | 0.040 |
Why?
|
Mouth | 1 | 2017 | 47 | 0.040 |
Why?
|
Enteral Nutrition | 1 | 2018 | 98 | 0.040 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2018 | 114 | 0.040 |
Why?
|
HEK293 Cells | 1 | 2019 | 600 | 0.040 |
Why?
|
Herpesvirus 1, Human | 1 | 2020 | 243 | 0.040 |
Why?
|
Acrylamides | 1 | 2017 | 30 | 0.040 |
Why?
|
Diagnostic Tests, Routine | 1 | 2017 | 57 | 0.040 |
Why?
|
Reference Values | 2 | 2009 | 659 | 0.040 |
Why?
|
Neck Dissection | 2 | 2008 | 65 | 0.040 |
Why?
|
MDS1 and EVI1 Complex Locus Protein | 1 | 2016 | 6 | 0.040 |
Why?
|
Regulatory-Associated Protein of mTOR | 1 | 2016 | 10 | 0.040 |
Why?
|
Aniline Compounds | 1 | 2017 | 44 | 0.040 |
Why?
|
Leukocytes, Mononuclear | 1 | 2018 | 191 | 0.040 |
Why?
|
Proportional Hazards Models | 1 | 2019 | 824 | 0.040 |
Why?
|
Osteonectin | 1 | 2016 | 22 | 0.040 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2016 | 68 | 0.040 |
Why?
|
Program Evaluation | 1 | 2018 | 288 | 0.040 |
Why?
|
MCF-7 Cells | 1 | 2016 | 103 | 0.040 |
Why?
|
Decision Making | 1 | 2002 | 602 | 0.040 |
Why?
|
Financing, Government | 1 | 2016 | 22 | 0.040 |
Why?
|
Immunoenzyme Techniques | 1 | 2016 | 299 | 0.040 |
Why?
|
Loss of Heterozygosity | 1 | 2016 | 84 | 0.040 |
Why?
|
Bayes Theorem | 1 | 2017 | 331 | 0.040 |
Why?
|
Comorbidity | 1 | 2019 | 915 | 0.040 |
Why?
|
Snake Venoms | 1 | 2015 | 10 | 0.040 |
Why?
|
Pilot Projects | 1 | 2018 | 792 | 0.040 |
Why?
|
Exons | 1 | 2017 | 441 | 0.030 |
Why?
|
Acid Anhydride Hydrolases | 1 | 2015 | 13 | 0.030 |
Why?
|
Microfilament Proteins | 1 | 2016 | 204 | 0.030 |
Why?
|
RNA Interference | 1 | 2016 | 356 | 0.030 |
Why?
|
Human papillomavirus 18 | 1 | 2014 | 15 | 0.030 |
Why?
|
Cause of Death | 1 | 2016 | 272 | 0.030 |
Why?
|
Biological Availability | 1 | 2014 | 91 | 0.030 |
Why?
|
Cell Division | 1 | 2016 | 688 | 0.030 |
Why?
|
Gene Knockout Techniques | 1 | 2014 | 76 | 0.030 |
Why?
|
Lymphatic Metastasis | 1 | 2016 | 467 | 0.030 |
Why?
|
Nonlinear Dynamics | 1 | 2014 | 75 | 0.030 |
Why?
|
Protein Interaction Maps | 1 | 2014 | 48 | 0.030 |
Why?
|
Tissue Distribution | 1 | 2014 | 277 | 0.030 |
Why?
|
Anorexia | 1 | 2014 | 29 | 0.030 |
Why?
|
Transcription, Genetic | 1 | 2019 | 1116 | 0.030 |
Why?
|
Metabolic Clearance Rate | 1 | 2014 | 119 | 0.030 |
Why?
|
Immunoblotting | 1 | 2014 | 265 | 0.030 |
Why?
|
Calcitonin | 1 | 2013 | 38 | 0.030 |
Why?
|
Erythrocyte Count | 1 | 2013 | 23 | 0.030 |
Why?
|
Carcinoembryonic Antigen | 1 | 2013 | 37 | 0.030 |
Why?
|
Leg | 1 | 2014 | 133 | 0.030 |
Why?
|
Algorithms | 2 | 2013 | 1776 | 0.030 |
Why?
|
Cotinine | 1 | 2013 | 12 | 0.030 |
Why?
|
NF-kappa B | 1 | 2016 | 422 | 0.030 |
Why?
|
Erythropoietin | 1 | 2013 | 89 | 0.030 |
Why?
|
Carrier Proteins | 1 | 2016 | 658 | 0.030 |
Why?
|
HeLa Cells | 1 | 2014 | 492 | 0.030 |
Why?
|
Microscopy, Atomic Force | 1 | 2013 | 48 | 0.030 |
Why?
|
Sequence Analysis, RNA | 1 | 2014 | 204 | 0.030 |
Why?
|
Sensitivity and Specificity | 1 | 2017 | 1939 | 0.030 |
Why?
|
Pyrazoles | 1 | 2014 | 148 | 0.030 |
Why?
|
Tolonium Chloride | 1 | 2012 | 5 | 0.030 |
Why?
|
Herpesvirus 4, Human | 1 | 2013 | 111 | 0.030 |
Why?
|
Risk Reduction Behavior | 1 | 2013 | 97 | 0.030 |
Why?
|
Coloring Agents | 1 | 2012 | 64 | 0.030 |
Why?
|
Saliva | 1 | 2013 | 114 | 0.030 |
Why?
|
Microscopy, Confocal | 1 | 2013 | 266 | 0.030 |
Why?
|
Asymptomatic Diseases | 1 | 2012 | 38 | 0.030 |
Why?
|
Vomiting | 1 | 2014 | 182 | 0.030 |
Why?
|
Self Report | 1 | 2013 | 270 | 0.030 |
Why?
|
Supraglottitis | 1 | 2011 | 3 | 0.030 |
Why?
|
Chemoradiotherapy, Adjuvant | 1 | 2011 | 34 | 0.030 |
Why?
|
Physical Examination | 1 | 2012 | 140 | 0.030 |
Why?
|
Neoplasm Proteins | 1 | 2015 | 530 | 0.030 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2012 | 191 | 0.030 |
Why?
|
Light | 1 | 2012 | 281 | 0.030 |
Why?
|
Cells, Cultured | 1 | 2016 | 2772 | 0.030 |
Why?
|
Radiation Dosage | 1 | 2011 | 224 | 0.030 |
Why?
|
Review Literature as Topic | 1 | 2010 | 17 | 0.020 |
Why?
|
Cross-Over Studies | 1 | 2011 | 392 | 0.020 |
Why?
|
Osteoradionecrosis | 1 | 2010 | 16 | 0.020 |
Why?
|
Postoperative Period | 1 | 2010 | 285 | 0.020 |
Why?
|
Mercury Compounds | 1 | 2009 | 1 | 0.020 |
Why?
|
Cadmium Compounds | 1 | 2009 | 2 | 0.020 |
Why?
|
Mice, Inbred C57BL | 1 | 2016 | 3052 | 0.020 |
Why?
|
ROC Curve | 1 | 2012 | 733 | 0.020 |
Why?
|
Hospitalization | 1 | 2014 | 764 | 0.020 |
Why?
|
Laboratories | 1 | 2009 | 38 | 0.020 |
Why?
|
Nitrogen | 1 | 2009 | 64 | 0.020 |
Why?
|
Tight Junctions | 1 | 2010 | 143 | 0.020 |
Why?
|
Cyclin D | 1 | 2008 | 13 | 0.020 |
Why?
|
Infant, Newborn | 1 | 2014 | 2272 | 0.020 |
Why?
|
Gene Dosage | 1 | 2009 | 206 | 0.020 |
Why?
|
Transcription Factor AP-1 | 1 | 2008 | 65 | 0.020 |
Why?
|
Azoxymethane | 1 | 2008 | 82 | 0.020 |
Why?
|
Rats, Inbred F344 | 1 | 2008 | 159 | 0.020 |
Why?
|
Cyclins | 1 | 2008 | 80 | 0.020 |
Why?
|
STAT3 Transcription Factor | 1 | 2008 | 70 | 0.020 |
Why?
|
Equipment Design | 1 | 2009 | 400 | 0.020 |
Why?
|
Organ Preservation | 1 | 2008 | 73 | 0.020 |
Why?
|
Glioblastoma | 1 | 2010 | 235 | 0.020 |
Why?
|
Infant | 1 | 2014 | 2928 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 860 | 0.020 |
Why?
|
Technology, Radiologic | 1 | 2008 | 102 | 0.020 |
Why?
|
Temperature | 1 | 2009 | 395 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2009 | 197 | 0.020 |
Why?
|
Child, Preschool | 1 | 2014 | 3522 | 0.020 |
Why?
|
Barrett Esophagus | 1 | 2008 | 91 | 0.020 |
Why?
|
Transfection | 1 | 2009 | 885 | 0.020 |
Why?
|
Forecasting | 1 | 2008 | 305 | 0.020 |
Why?
|
Protein Structure, Tertiary | 1 | 2009 | 731 | 0.020 |
Why?
|
Body Mass Index | 1 | 2009 | 743 | 0.020 |
Why?
|
Blotting, Western | 1 | 2008 | 772 | 0.020 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2006 | 123 | 0.020 |
Why?
|
Phospholipids | 1 | 2006 | 108 | 0.020 |
Why?
|
Pleural Effusion | 1 | 2004 | 44 | 0.020 |
Why?
|
Genome, Human | 1 | 2010 | 740 | 0.020 |
Why?
|
Organoplatinum Compounds | 1 | 2004 | 94 | 0.020 |
Why?
|
Administration, Topical | 1 | 2003 | 89 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2010 | 1930 | 0.020 |
Why?
|
Genome-Wide Association Study | 1 | 2011 | 1534 | 0.020 |
Why?
|
In Situ Hybridization | 1 | 2003 | 303 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2010 | 1159 | 0.010 |
Why?
|
Survival | 1 | 2002 | 22 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2008 | 1683 | 0.010 |
Why?
|
Registries | 1 | 2006 | 647 | 0.010 |
Why?
|
Rats | 1 | 2008 | 3904 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2006 | 1737 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2013 | 3116 | 0.010 |
Why?
|